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Jan J. A. M. van den Dungen, MD, PhD, and Clark J. Zeebregts, MD, PhD, Groningen, The Netherlands
Objective: The objective of this study was to determine whether long-term follow-up after endovascular aneurysm repair
(EVAR) is justiﬁed in octogenarians.
Methods: Between September 1996 and October 2011, all patients, including octogenarians, treated for an abdominal
aortic aneurysm (AAA) by EVAR were included in a prospective database. Patients older than 80 years and with a
nonruptured infrarenal aneurysm treated electively or urgently were included in the study (study group [SG]). Patients
with ruptured aneurysms and patients who died during surgery or within the ﬁrst postoperative month were excluded
from further analysis. The control group (CG) consisted of patients younger than 80 years, matched for gender and AAA
diameter. All patients were evaluated 4 to 8 weeks after EVAR and then annually thereafter. Follow-up data were
complemented by review of the computerized hospital registry and charts and by contact of the patient’s general prac-
titioner or referring hospital. Primary outcomes were stent- or aneurysm-related complications and interventions. Sec-
ondary outcomes were additional surgical complications and patient survival.
Results: A total number of 193 patients (SG, n[ 97; CG, n[ 96) were included for analysis. Median age was 80 years,
and 88.6% were male. Median follow-up time was 33.6 months (interquartile range [IQR], 12.9-68.3). Stent- and
procedure-related postoperative complications were comparable between groups (SG, 41.2%; CG, 39.6%; P [ .82).
Median time to complication was 2.3 months (IQR, 0.2-19.4) in the SG compared with 18.1 months (IQR, 6.8-50.5) in
the CG. The 2-year complication-free survival rates were 58% (SG) and 60% (CG). Interventions were performed
signiﬁcantly less frequently in octogenarians (SG, 8.2%; CG, 19.8%; P < .05). Median time to intervention was
11.1 months (IQR, 2.0-31.0) in the SG compared with 54.3 months (IQR, 15.0-93.2) in the CG. The 2-year
intervention-free survival rates were 90% (SG) and 92% (CG). During follow-up, 98 patients died (SG, n [ 54; CG,
n [ 44); median time to death was 31.8 months (IQR, 13.3-66.0) in the SG compared with 44.4 months (IQR, 15.0-
77.7) in the CG. One aneurysm-related death occurred in the CG. The 2- and 5-year survival rates were 71% and 32% for
the SG compared with 77% and 66% for the CG (P < .05).
Conclusions: Because of the low incidence of secondary procedures and AAA-related deaths in octogenarians, long-term
and frequent follow-up after EVAR seems questionable. An adapted and shortened follow-up seems warranted in this
patient group. (J Vasc Surg 2014;59:1232-40.)During the past decades, the life expectancy in the
Western world has increased steadily. In The Netherlands,
the number of people older than 80 years has increased
from 3.2% in 2000 to 4.2% in 2013.1 A similar growth is
also observed in the United States, where the cohort of oc-
togenarians has increased from 3.3% in 2000 to 3.6% in
2010.2 Reports further indicate that the number of octoge-
narians will continue to rise in the coming years.3 As an
abdominal aortic aneurysm (AAA) is an age-related disease,
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2will continue to rise. Even though the life expectancy of oc-
togenarians increases after aortic aneurysm repair, this pa-
tient population is highly susceptible to postoperative
complications, especially after open repair.4-7 With the
introduction of endovascular aneurysm repair (EVAR), oc-
togenarians can be offered a much less invasive treatment,
making EVAR the preferred treatment in this vulnerable
group.8-13
Although EVAR is associated with much less morbidity
and fewer short-term complications than in open repair,
stent graft-related complications such as endoleak and stent
fractures or occlusions are challenging and difﬁcult-to-treat
complications.13,14 According to the current literature, the
intervention rate after EVAR is estimated at 10% per year,
and therefore lifelong patient surveillance is currently rec-
ommended.15 With an already natural limited life expec-
tancy (mean survival of 6.1 years), octogenarians are
more likely to die of other causes than those related to
the aneurysm.16 Therefore, frequent and accurate moni-
toring for endoleak development or stent graft migration
is probably of less importance in the elderly compared
with their younger counterparts. Whether watchful waiting
JOURNAL OF VASCULAR SURGERY
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patients, is not yet known. The aim of this study was to
determine the complication and intervention rates after
EVAR in octogenarians compared with those in younger
patients. In addition, the time between EVAR and occur-
rence of complications or interventions was assessed to
evaluate whether a customized follow-up is applicable.
METHODS
Design of the study. Between September 1996 and
October 2011, 1160 patients underwent EVAR for an
infrarenal aortic aneurysm; 115 patients were 80 years or
older at the time of surgery. Exclusion criteria were a
ruptured aneurysm (n ¼ 17) and death during surgery or
within the ﬁrst postoperative month (n ¼ 1). The remain-
ing 97 patients formed the study group (SG). A control
group (CG, n ¼ 96) was composed of patients younger
than 80 years and matched for gender and AAA diameter.
For one patient, no match could be found. All patients gave
full informed consent before surgery after being informed
about the surgery and possible complications as well as al-
ternatives for EVAR, such as open aortic surgery or watch-
ful waiting. Preoperative collected data included age,
gender, American Society of Anesthesiologists (ASA) score,
and Charlson Comorbidity Index.17,18 Intraoperative pre-
dictors were duration of surgery, type of anesthesia, anat-
omy and aneurysm conﬁguration, type of AAA repair, and
stent graft device. Postoperative predictors and outcome
were hospital length of stay, intensive care unit admittance,
and stent- and surgery-related complications. Surgical
complications were classiﬁed according to the Clavien-
Dindo Classiﬁcation of Surgical Complications.19,20
Procedure. All procedures were performed at our uni-
versity medical center by an interdisciplinary team consist-
ing of vascular surgeons experienced with all types of
devices, an interventional radiologist, and an anesthesiolo-
gist. The preferred type of anesthesia was local anesthesia,
which was applied in 74.1% of patients (SG, 82.5%; CG,
65.6%). In case of pain despite local anesthesia, adiposity,
or previous groin surgery, regional (SG, 9.3%; CG,
18.8%) or general (SG, 8.2%; CG, 15.6%) anesthesia was
applied. The choice for either alternative was based on
the patient’s and anesthesiologist’s preference.
All the devices used were CE (Communauté Europé-
enne) Mark-approved; they included different types of stent
grafts from various companies, including Boston Scientiﬁc
Vascular, Cook Medical, Cordis, Medtronic, Vascutek
Ltd, andW. L. Gore and Associates. In general, we attended
to the speciﬁc instructions for use as proposed by the
manufacturing companies. Both the technique and the con-
siderations for EVAR have been published previously.21
Follow-up. All patients received computed tomo-
graphic angiography between 4 and 8 weeks after EVAR
to assess the position and conﬁguration of the stent graft
and to detect new or previously unnoticed endoleaks.
Patients were further monitored with an annual four-view
abdominal radiograph and duplex ultrasound scan. Primary
outcome measures were any stent- or aneurysm-relatedcomplication and the subsequent intervention. The endo-
leak types were categorized according to the classiﬁcation
described by White et al.22 Further attention was given to
aneurysm growth; stent graft migration, kinking, throm-
bosis, and occlusion; any type of stent graft failure (including
type III and type IV endoleak); and stent graft infections.
Stent graft kinking was graded by the system as recom-
mended by Chaikof et al. In this system, grade I signiﬁes
induced curvature, without acute angulation. Grade II in-
dicates angulation of more than 30 degrees, and grade III
refers to angulation of more than 30 degrees along with
obstruction of the device (IIIa) or disconnection (IIIb).23
Stent graft thrombosis was deﬁned as a reduction of the
lumen diameter >50% based on mural thrombus visible on
duplex ultrasound examination independent of clinical signs.
Interventions were classiﬁed as endovascular leg or
body extension, coiling of target vessels, endovascular
relining, crossover bypass, and conversion to open repair.
Secondary outcome measures were additional surgical
complications and patient survival.
Statistical analysis. Categorical variables were pre-
sented as numbers or percentages. Continuous variables
were presented as median and interquartile range (IQR).
In cases of fewer than ﬁve events, continuous variables
were expressed as mean with standard deviation because
no reliable IQR could be calculated. Categorical variables
were analyzed by means of the c2 test or Fisher exact test.
Continuous variables were tested with the Student t-test
for normal distribution and the Mann-Whitney U test
for skewed distribution. Complication- and intervention-
free survival rates were calculated by means of Kaplan-
Meier analysis. Differences in survival and outcome were
determined by log-rank testing. Two-tailed P values were
used throughout, and signiﬁcance was set at P < .05. All
statistical analyses were done with the Statistical Package
for the Social Sciences (SPSS 16.0.1; SPSS, Chicago, Ill).
RESULTS
Patients and procedures
The majority of patients were treated for an asymptom-
atic aneurysm (SG, 89.7%; CG, 96.9%). The remainder
(SG, 10.3%; CG, 3.1%) were symptomatic aneurysms,
which required more urgent treatment. ASA classiﬁcation
was determined by the anesthesiologist. All patients were
assigned to ASA grade II (SG, 53.6%; CG, 50%) and grade
III (SG, 46.4%; CG, 50%). Patient characteristics are sum-
marized in Table I. Twelve patients experienced intraoper-
ative complications (SG, n ¼ 4; CG, n ¼ 8). These
complications are stated in Table II.
Stent graft-related complications
Seventy-eight patients (40.4%; SG, 41.2%; CG, 39.6%;
P ¼ .82) developed 145 (SG, n ¼ 63; CG, n ¼ 82) stent-
related complications after EVAR after a median of
12.9 months (IQR, 2.9-38.5). Thirty-eight patients had
one complication (SG, n ¼ 23; CG, n ¼ 15), 22 patients
had two complications (SG, n ¼ 12; CG, n ¼ 10), and 18
Table I. Baseline characteristics
Parameter Total (N ¼ 193) Patients $80 years (n ¼ 97) Patients <80 years (n ¼ 96) P value
Age, years 80 (72-82) 82 (81-84) 72 (65-76)
Gender, male 171 (88.6) 86 (88.7) 85 (88.5)
ASAa 2 (2-3) 2 (2-3) 2 (2-3) .83
Comorbidity (CCI)b 6 (5-7) 6 (5-7) 5 (4-6) <.05
AAA diameter, mm 60 (56-68) 60 (57-68) 60 (56-68)
Urgency (elective) 180 (93.3) 87 (89.7) 93 (96.9) <.05
Duration of surgery, minutes 130 (110-159) 141 (113-165) 120 (100-140) <.05
ICU admittance, No. of patients 3 (1.6) 1 (1.0) 2 (2.1) .62
ICU admittance, days 2 2 2 NA
Hospital length of stay, days 5 (4-6) 5 (4-6) 5 (4-7) .82
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; ICU, intensive care unit; IQR, inter-
quartile range; NA, not applicable.
Categorical variables are presented as number (%) and continuous variables are presented as median and IQR. P values < .05 were considered signiﬁcant.
aASA score: ﬁve-category physical classiﬁcation system for assessing the ﬁtness of patients before surgery.
bCCI: predicts the 1-year mortality by scoring of the patients’ comorbidities.
Table II. Intraoperative complications
Type of complication Total, No. (%) Patients $80 years, No. (%) Patients <80 years, No. (%) P value
Iliofemoral crossover bypass necessary 1 (1.0) 1 (1.0) 0 (0) NA
Internal iliac artery occlusion 9 (4.7) 2 (2.1) 7 (7.3) .10
Conduit necessary for access 1 (1.0) 1 (1.0) 0 (0) NA
Bridging stent graft necessary 1 (0.5) 0 (0) 1 (1.0) NA
Total 12 (6.2) 4 (4.1) 8 (8.3) .23
NA, Not applicable.
P values < .05 were considered signiﬁcant.
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related complications during follow-up. There were signiﬁ-
cantly more patients who had interventions in the CG
compared with the SG (SG, 8.2%; CG, 19.8%; P ¼ .02).
In the SG, median time to complication was 2.3 months
(IQR, 0.2-19.4). Forty-one complications (41 of 63; 65.1%)
occurred within the ﬁrst 12 months after the initial EVAR.
The accompanying 2-year complication-free survival was
58% (Fig 1). A total of nine interventions were necessary in
eight patients (8.2%). Median time to intervention was
11.1 months (IQR, 2.0-31.1) (Table III). Six interventions
(6 of 9; 66.7 %) were performed within the ﬁrst year after
EVAR. The 2-year intervention-free survival was 92%
(Fig 2). EVAR-related complications and secondary inter-
ventions in the SG were independent of sex (P ¼ .11 and
P¼ .91, respectively), urgency (P¼ .21 and P¼ .83, respec-
tively), ASA score (P¼ .82 andP¼ .83, respectively), comor-
bidity (P¼ .07 andP¼ .58, respectively), orAAAdiameter at
the time of EVAR (P ¼ .55 and P ¼ .25, respectively).
In the CG, median time to complication was
18.1 months (IQR, 6.8-50.5). Nineteen patients (19.8%)
had 27 interventions after a median of 54.3 months
(IQR, 15.0-93.2) (Table IV).
In the following paragraphs, the individual complica-
tions are addressed.
Endoleak. A total of 36 endoleaks, including types
Ia, Ib, II, and III, occurred in 34 patients (35.1%) in the
SG compared with 36 endoleaks in 29 patients (30.2%)in the CG. Intervention was performed in 16.7% of endo-
leaks in the SG (6 of 36) compared with 44.4% in the CG
(16 of 36).
Type Ia endoleak occurred in 11 patients (5.7%), with
no signiﬁcant difference between the SG (5.2%) and the
CG (6.5%). In three patients (3 of 11, 27.3%), successful
placement of a proximal extension was performed (SG, 2
of 5 [40%]; CG, 1 of 6 [16.7%]). In seven patients
(3.6%), type Ib endoleaks were detected (SG, 1.0%; CG,
6.3%). All type Ib endoleaks in the CG were corrected.
The patient in the SG declined further follow-up.
The most common complication was a type II endoleak
that occurred in 45 patients (23.3%), with no signiﬁcant
difference between the SG (27.8%) and the CG (18.8%;
P ¼ .18). Two patients in the SG (2 of 27; 7.4%) under-
went coiling because of aneurysm growth. In one patient,
a previously unnoticed type III endoleak was discovered,
for which an endovascular relining was necessary. One pa-
tient had unsuccessful coiling, and after 3 months, the
endoleak spontaneously disappeared. The remaining 25 pa-
tients (25 of 27; 92.6%) had a “wait-and-see” approach. In
13 patients (13 of 25; 52.0%), the endoleak disappeared
over time; and in 12 patients (12 of 25; 48.0%), an inter-
vention was waived because of frailty of the patient or
limited or absent aneurysm growth. No aneurysm-related
deaths occurred in the SG during follow-up. In the CG,
an intervention was necessary in ﬁve patients who presented
with type II endoleak (5 of 18; 17.8%).
Fig 1. Probability of complication-free survival after endovascular aneurysm repair (EVAR): Comparison of patients
$80 years of age and patients <80 years (according to the Kaplan-Meier method). There is no statistical signiﬁcance
between the two groups (log-rank, P ¼ .27).
Table III. Endovascular aneurysm repair (EVAR)-related complications in patients $80 years
Type of complication No. (%) Time since EVAR, months
Intervention,
No. (%) Time since EVAR, months
Disappeared,
No. (%)
Type Ia endoleak 5 (5.2) 0.03 (0.01-1.1)a 2 (40) 2.0 6 2.7b 3 (60)
Type Ib endoleak 1 (1.0) 29.5 0 (0) 0 (0)
Type II endoleak 27 (27.8) 1.9 (0.1-2.4)a 2 (7.4) 9.5 6 2.3b 13 (48.1)
Type III 3 (3.1) 28.1 6 19.8b 2 (66.7) 31.2 6 28.4b 0 (0)
Migration 6 (6.2) 15.9 (5.5-26.4)a 2 (33.3) 31.1 6 10.0b 0 (0)
Kinking 8 (8.2) 12.3 (0.5-36.6)a 0 (0) 0 (0)
Thrombosis 2 (2.1) 6.3 6 8.9b 1 (50) 0.03 0 (0)
Growth 11 (11.3) 12.4 (4.9-31.1)a
Total 63 (40 patients; 41.2%) 2.3 (0.2-19.4)a 9 (8 patients; 8.2%) 11.1 (2.0-31.1)a 16 (25.4)
aPresented as median and interquartile ranges.
bPresented as mean 6 standard deviation.
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consisting of a type III endoleak, with no signiﬁcant differ-
ence between the groups (SG, 3.1%; CG, 6.3%; P ¼ .33).
In the SG, two patients (2 of 3; 66.7%) had an intervention
consisting of endovascular relining and leg extension,
respectively (CG, 4 of 6; 66.7%). One patient did not
receive an intervention because of lack of aneurysm
growth. There were no type IV endoleaks identiﬁed.
Stent graft migration, kinking, and thrombosis or
occlusion. Stent graft migration occurred six times in ﬁve
patients (5.2%) in the SG. Two patients (2 of 5; 33.3%)needed an intervention consisting of a unilateral leg
extension and conversion to open repair with an aortic
bifurcation graft, respectively. In the remainder, no inter-
ventions were performed, as the migration was not consid-
ered severe enough. In the CG, migration of the graft was
detected in six patients (6.3%), and two patients (2 of 6;
33.3%) needed an intervention.
Stent graft kinking was seen in 25 patients (13%), with
no statistical difference between groups (SG, 8.2%; CG,
17.7%; P ¼ .05). Two interventions were performed in
the CG (2 of 17; 11.8%). In the SG, none of the cases
Fig 2. Probability of intervention-free survival after endovascular aneurysm repair (EVAR): Comparison of patients
$80 years of age and patients <80 years (according to the Kaplan-Meier method). There is no statistical signiﬁcance
between the two groups (log-rank, P ¼ .48).
Table IV. Endovascular aneurysm repair (EVAR)-related complications in patients <80 years
Type of complication No. (%) Time since EVAR, months
Intervention,
No. (%)
Time since EVAR,
months
Disappeared,
No. (%)
Type Ia endoleak 6 (6.3) 0.7 (0.01-81.1)a 1 (16.7) 9.5 1 (16.7)
Type Ib endoleak 6 (6.3) 34.6 (21.1-73)a 6 (100) 53.0 6 40.4b 0 (0)
Type II endoleak 18 (18.8) 4.3 (1.6-29.7)a 5 (27.8) 67.7 6 34.2b 5 (27.8)
Type III 6 (6.3) 84.3 6 64.7b 4 (66.7) 112.5 6 68.2b 0 (0)
Migration 6 (6.3) 29.3 (13.1-38.6)a 2 (33.3) 39.5 6 11.3b 0 (0)
Kinking 17 (17.5) 13 (11.9-24)a 2 (11.8) 39.3 6 6.0b 0 (0)
Thrombosis 6 (6.3) 32.7 (2.9-101.8)a 6 (100) 51.5 6 50.7b 0 (0)
Growth 16 (16.7) 37.9 (13.3-55.1)a
Infection 1 (1.0) 67.9 1 (100) 67.9 0 (0)
Total 82 (38 patients; 39.6%) 18.1 (6.8-50.5)a 27 (19 patients; 19.8%) 54.3 (15.0-93.2)a 6 (7.3)
aPresented as median and interquartile ranges.
bPresented as mean 6 standard deviation.
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watchful policy was implemented, after which no further
complications occurred.
Stent graft thrombosis or occlusion was seen in eight
patients (4.1%), with no signiﬁcant difference between
the SG (2.1%) and the CG (6.3%). In the SG, occlusion
of the graft was observed in one patient on the ﬁrst postop-
erative day, after which surgical thrombectomy and endo-
vascular relining were performed. In the second patient,
an asymptomatic 50% stenosis was visible on duplexscanning, which was later diagnosed as thrombus on a
computed tomography scan.
In the CG, all patients had secondary interventions.
Aneurysm growth. In the SG, there was persistent
aneurysm growth after EVAR in 11 patients (11.3%),
mainly due to type II endoleaks (7 of 11; 63.6%). Other
causes of aneurysm growth after EVAR were type Ia (1
of 11; 9.1%), type Ib (1 of 11; 9.1%), and type III endoleak
(1 of 11; 9.1%). In one patient, no apparent cause of the
aneurysm growth could be determined. Two type II
Fig 3. Probability of survival after endovascular aneurysm repair (EVAR): Comparison of patients $80 years of age
and patients <80 years (according to the Kaplan-Meier method). There is statistical signiﬁcance between the two
groups (log-rank, P < .05).
Table V. Causes of death
Total,
No. (%)
Age
$80 years,
No. (%)
Age
<80 years,
No. (%) P value
Aneurysm-related 1 (.5) 0 (0) 1 (1.0) NA
Neurologic 3 (1.6) 1 (1.0) 2 (2.1) .62
Cardiac 11 (5.7) 5 (5.2) 6 (6.3) .74
Pulmonary 12 (6.2) 10 (10.3) 2 (2.1) <.05
Malignant disease 20 (10.4) 6 (6.2) 14 (14.6) .06
Multiorgan failure 4 (4.1) 0 (0) 4 (4.2) NA
Other 15 (7.8) 12 (12.4) 3 (3.1) <.05
Unknown 32 (16.6) 20 (20.1) 12 (12.5) .13
Total 98 (50.8) 54 (55.7) 44 (45.8) .22
NA, Not applicable.
P values < .05 were considered signiﬁcant.
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was corrected by placement of an extension, and the type
III endoleak was corrected by endovascular relining. In six
patients, a wait-and-see policy seemed permissible. In one
patient, the cause of aneurysm growth was unknown. How-
ever, after initial growth of the aneurysm, the diameter
remained stable during follow-up. In all other patients,
endoleak type II was the underlying cause of aneurysm
growth. In one patient, the size of the aneurysm did not
increase any further during follow-up after the initial growth
was adjusted. In the remaining three patients, advanced age
and comorbidity were the main reasons to suppose that the
beneﬁts of an intervention would not outweigh the negative
side effects. Along with the opinion of the surgeon, the wish
of the patient played a major role in the decision-making in
these cases. One patient refused further treatment.
Aneurysm growth was detected in 16 patients (16.7%)
in the CG.
Infection. Infectionof the stent graft didnot occur in the
SGduring follow-up. In theCG,onepatient (1.0%)presented
with infection, and this patient had immediate surgery.
Additional surgical complications
Thirty-nine patients (SG, n ¼ 24; CG, n ¼ 15; P ¼ .1)
experienced surgical complications as classiﬁed by the
Clavien-Dindo system.19,20 In 23 patients (SG, n ¼ 10;CG, n ¼ 13), the complication was speciﬁed as a grade I
complication, deﬁned by any deviation from the normal
postoperative course without the need for pharmacologic
treatment. In 15 patients (SG, n ¼ 13; CG, n ¼ 2), phar-
macologic treatment was necessary (grade II). One patient
in the SG required a surgical intervention (grade III).
Patient survival
Ninety-eight patients (SG, n ¼ 54; CG, n ¼ 44; P ¼
.2) died during follow-up. The median survival was
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44.4 months (IQR, 15.0-77.7) in the CG. The 2- and 5-
year survival rates were 71% and 32% (SG) and 77% and
66% (CG) (Fig 3). The estimated risk for death was signif-
icantly higher in the SG compared with the CG (log-rank,
P < .05). One patient in the CG died of a ruptured aneu-
rysm. Sixty-ﬁve patients (65 of 98; 66.3%) died of unre-
lated causes; in 32 patients (32 of 98; 32.7%), the cause
of death could not be ascertained despite close follow-up
(Table V).DISCUSSION
This study shows that although stent-related complica-
tions after EVAR certainly occur in the elderly, 65.1%
occur within the ﬁrst year after EVAR. Also, only 8.2% of
octogenarians will undergo an intervention without
affecting the number of AAA-related deaths. Therefore,
one may wonder whether long-term and frequent follow-
up after EVAR is necessary. Previous studies have found
that the higher rates of endoleak in octogenarians do not
increase the risk of interventions or ruptures.24,25 Because
an intervention was actually indispensable in only a minor-
ity of patients in our SG, the majority of registered compli-
cations during follow-up can be considered of minor
importance. This in turn could mean that 90% of octoge-
narians currently are receiving follow-up for no apparent
reason. Although more research is clearly necessary for a
deﬁnitive conclusion to be reached, octogenarians should
be approached differently from their younger counterparts.
Impaired mobility, multiple pathologic processes, and
medicine use make regular follow-up a mental and physical
strain in octogenarians. In dealing with frail elderly pa-
tients, the risks must always be balanced against the bene-
ﬁts of surgery. Even though good results after EVAR have
been reported, one can raise questions on costs and beneﬁt.
With the current climate of cost containment and limited
reimbursement for health care delivery, a critical analysis
of the costs vs relative beneﬁts remains important, certainly
in treating octogenarians, for whom median survival re-
mains limited by the natural life expectancy. Current liter-
ature clearly shows that EVAR is appreciably more
expensive than open repair. Also, the decreased length of
stay in the intensive care unit and hospital does not
compensate for the cost of EVAR. With the proposed re-
ductions in reimbursement, the ability to cover the cost
may be threatened. Because long-term surveillance is
considered mandatory after EVAR, the follow-up costs
will further increase the cost disparity between EVAR
and open repair.
Our results with regard to EVAR-related complications
are consistent with the current literature.15,24 We found a
signiﬁcant difference when it comes to intervention rates
between octogenarians and patients younger than 80 years
(8.2% vs 19.8%; P < .05). Moreover, younger patients un-
derwent three times more interventions compared with oc-
togenarians (CG, n ¼ 27; SG, 9). In octogenarians,
watchful waiting was considered sufﬁcient on the basis ofadvanced age. This seems to be a justiﬁable choice when
the low AAA-related death rate is taken into account.
In recent years, there has been a huge paradigm shift
with respect to the treatment of octogenarians, and AAA
repair has proved to be a safe procedure in this vulnerable
group.25-27 The shorter hospitalization period and quick
return to former level of functioning are of vital importance
for octogenarians, making EVAR the treatment of choice.
In terms of quality of life, it has been established that for
the most part, this is preserved in octogenarians after
EVAR.14 Follow-up, with hospital visits preceding burden-
some and sometimes harmful tests, may be experienced as
stressful by older patients. In our series, this has even led to
a signiﬁcantly higher rate of patients lost to follow-up in the
SG compared with the CG (P < .05). When asked, the ma-
jority of patients indicated that the outpatient visits were
becoming burdensome. A reduction in the amount of out-
patient clinic visits could increase quality of life and reduce
costs. The diagnostic costs after EVAR account for 8.2% of
the total hospital costs ($1760 of $21,250), compared
with 5.7% after open repair ($698 of $12,342).28 This differ-
ence increases with longer follow-up.29
Of the 54 patients in the SG (55.7%) who died during
follow-up, no deaths were aneurysm-related. These ﬁgures
correspond with the literature and contribute to the
growing doubt as to whether a long-term follow-up is
really meaningful or just common practice.13,30,31
The majority of complications in our SG (42.9%) were
type II endoleaks, and 48.1% disappeared without an inter-
vention. Although this percentage is less than reported in
the literature, a signiﬁcant part vanishes over time.32 A
possible explanation for the lower rate in our series is
that we considered type II endoleaks signiﬁcant when still
visible by computed tomographic angiography 8 weeks
postoperatively. By exclusion of small endoleaks visible at
the completion angiogram, a higher percentage of persis-
tent endoleaks remain. Conservative treatment of type II
endoleaks is considered safe in the absence of aneurysm
growth.33
Although the incidence of complications after EVAR
has signiﬁcantly decreased in recent years, it is expected
that with the advent of new technologies and further
growth of complex EVAR expertise, complication rates
will be even lower.12,34 This is further supported by the
fact that 46.9% of patients in our study who had surgery
between 1996 and 2005 had one or more complications
compared with only 33.7% treated between 2006 and
2011 (P ¼ .06). Furthermore, only 4.2% of patients who
were treated between 2006 and 2011 required an interven-
tion compared with 23.5% of patients who were treated be-
tween 1996 and 2005 (P < .05).
The 2- and 5-year actuarial survival rates in our SG are
71% and 32% (CG, 77% and 66%). These results are fairly
similar to the literature with reported 2-year survival rates
of 68%, although outliers with an 8-year survival of 64%
are also reported.25,35
As our study has a great time range, many different
stent grafts have been used in the study population.
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shrinkage has been described. The authors concluded
that newer-generation devices have a greater effect on
aneurysm shrinkage lasting up to 10 years.36 This would
also mean that a shorter follow-up period is even more
justiﬁable with newer stent grafts.
This study has some limitations that need to be
addressed. Although an intention-to-treat principle was
applied, we excluded one patient who died of cardiac arrest
within the ﬁrst month after surgery. We thought that this
was a legitimate choice in a study focusing on postoperative
complications. In addition, we believe that this one patient
would not have altered the results. We adopted a strategy
to treat all patients unless they had a very poor performance
score (Karnofsky performance score # 40).4 As such, 95%
of the patients received full treatment regardless of age,
making it unlikely that a selection bias based on urgency
has occurred. Ruptured aneurysms were excluded as the
risk of complications is considerably higher in these patients
compared with patients undergoing elective operation.37
In terms of safety, however, it was shown recently that oc-
togenarians with a ruptured AAA can be treated with a
more than acceptable outcome.4 In this study, 12.4% of
patients had an AAA diameter of <55 mm. Although a
diameter of 55 mm is internationally accepted as the
threshold for intervention, it is justiﬁed to perform surgery
in patients with rapid aneurysm growth (>5 mm in the last
6 months) (n ¼ 7), symptoms (n ¼ 1), saccular aneurysms
(n ¼ 3), and familial predisposal for aneurysms (n ¼ 2).38
Our CG consisted of a matched group of patients younger
than 80 years at the time of the procedure. Unfortunately,
for one patient in the SG, no sufﬁcient match could be
found. All data from a prospectively held database were
retrospectively analyzed. Also, a large part of the study
population consisted of a historical cohort, and as a result
detailed anatomic characteristics are lacking. Hence, it
was not possible to reliably determine which patients
were treated outside the instructions for use.
In 20 patients in the SG, the cause of death could not
be reliably ascertained. As a result, a number of patients
could still have died of an aneurysm-related cause and
gone unnoticed. A relative underestimation of the
aneurysm-related death rate therefore cannot be ruled
out. However, in these patients, the median time interval
between the last follow-up visit and death was 4.4 months
(IQR, 3.1-15.8). Also in 80% of patients, there were no
aneurysm- or stent graft-related complications during the
last follow-up. Therefore, the probability of aneurysm-
related deaths in this group is very small.
CONCLUSIONS
In this study, the incidence of interventions and AAA-
related death was lower in octogenarians than in younger
patients. Therefore, an adapted and shortened follow-up
seems warranted in octogenarians after EVAR. A shortened
follow-up will most likely have no effect on patient survival
but may lower the total amount of EVAR costs and increase
quality of life. In patients with any type of complication,additional follow-up is recommended. More research is
needed to conﬁrm the results of this study. Ideally, after
greater insights are obtained into stent-related complica-
tions, tailor-made follow-up schemes regarding duration
and intensity could be developed.
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